Development and Validation of Spectrophotometric and Chromatographic Method for the Estimation of Apremilast in Bulk and Formulations
Objective: Objective of the present analytical research work was to develop and validate Spectrophotometric method and High Performance Liquid Chromatographic method (HPLC Method) for the Apremilast bulk and tablets dosage form.
Methods: A spectrophotometric method and a HPLC method have been developed and validated for estimation of APR in pharmaceutical oral dosage form.
Method A (UV SPECTROMETRY Method): The stock and working standard solutions of the drugs were prepared in methanol. Standard solutions were scanned over the range of 400-200 nm in spectrum mode of spectrophotometer at medium scanning speed using UV spectrophotometer. The maximum absorbance for Apremilast was found at 230 nm.
Method B (HPLC Method): The HPLC Method for Apremilast was developed using Cosmosil C18 (4.6mm x 250mm, Particle size: 5µm), as stationary particle, isocratic mode. Methanol: Water (80:20v/v) pH3 as mobile phase. Mobile phase was maintained at a flow rate of 0.8 ml/min and detection was carried out at 230 nm. Both the methods were validated in accordance with ICH guidelines
Results: Apremilast was found to be linear in the concentration range of 2-10 µg/ml for spectrophotometric method and 10-50 µg/ml for HPLC method. Retention time was found to be 4.0 min for Apremilast. The amount of Apremilast in marketed formulation by spectrophotometric method was found to be 99.82 %, the amount of Apremilast in marketed formulation by HPLC method was found to be 99.98 %.
Interpretation and Conclusion: Results of assay and validation study were found to be satisfactory. So, the methods can be successfully applied for the routine analysis of Apremilast.
Keywords: HPLC, bulk dosage form, tablets,
2. Beckett AH and Stenlake JB. Practical Pharmaceutical Chemistry, Part-II, 4th Ed., New Dehli; CBS Publishers and Distributors, 2004; 85- 174.
3. Willard HH, Merrist LL, Dean AJ, Frank A and Settle AF. Instrumental Methods of Analysis, 7th Ed., New Dehli; CBS Publishers and Distributors, 1986; 2-3, 585-587
4. Skoog DA, Holler FJ and Nieman TA. Principle of Instrumental Analysis, 5th Ed., Thomson Publication Limited, London, 2004; 103.
5. Sethi PD., High Performance Liquid Chromatography, Quantitative Analysis of Pharmaceutical Formulations, 1st edition, New Delhi; CBS Publishers and Distributors, 2001; 3-11, 116-120.
6. Toomula N, Kumar A, Kumar S, Bheemidi VS. Development and Validation of Analytical Methods for Pharmaceuticals & Bioanalytical Techniques, 2011; 2(5): 1-4.
7. Lakshmi SRP. A Review on Chromatography with High Performance Liquid Chromatography (HPLC) and its Functions. Research and Reviews: Journal of Pharmaceutical Analysis, March 2015; 4(1):1-15.
8. Swartz ME. HPLC: An introduction and review. J Liq Chromatogr Rel Technol. 2005; 25:1253–63.
9. Panchumarthy R, Shaheem S, Kamma HS, Development and Validation of a Stability-Indicating Reversed Phase Hplc Method for Determination of Apremilast in Bulk and Pharmaceutical Dosage Form, Der Pharmacia Lettre, 2017; 9 :63-73.
10. Lonkar NA, Sawant SD, Dole MN, Development and validation of stability indicating rp-hplc method for estimation of Apremilast by forced degradation studies, wjpps, 6(4):1493-1502.
11. Rele RV, Patil SP, Reversed Phase High Performance Liquid Chromatography Method for Determination of Assay and Forced Degradation Study of Apremilast from Active Pharmaceutical Dosage Form, Journal of Chemical and Pharmaceutical Research, 2018; 10(7):139-144.
12. Panchumarthy R, Sulthana MDS, Srinivasa Babu P, Development and validation of stability-indicating UV spectrophotometric method for determination of Apremilast in bulk and pharmaceutical dosage form, Indian Journal of Research in Pharmacy and Biotechnology, 2017; 5(1):47-53.
13. Chakravarthy AV, Sailaja BBV, Praveen KA, method development and validation of uv-visible spectroscopic method for estimation of assay of sugammadex sodium, Apremilast, riociguat and vorapaxar sulfate drugs in active pharmaceutical ingredient form, Asian J Pharm Clin Res, 2017; 10(2):241-250.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeÂ The Effect of Open Access).